Regional heterogeneity of α-adrenoreceptor subtypes in arteriolar networks of mouse skeletal muscle.
Activation of vascular adrenoreceptors (ARs) governs the magnitude and distribution of muscle blood flow in accord with the distribution of AR subtypes. Functional studies in the rat cremaster muscle indicate that α1ARs predominate in proximal arterioles (first-order, 1A) while α2ARs predominate in distal arterioles (third-order, 3A). However, little is known of AR subtype distribution in arteriolar networks of locomotor skeletal muscles, particularly in the mouse. We tested the hypotheses that functional AR subtypes exhibit heterogeneity among branches of arteriolar networks in a locomotor muscle and that the nature of this heterogeneity can vary between muscles having diverse functions. In anaesthetized male C57BL/6J mice (3 months old), concentration-response curves (10(-9) m to 10(-5) m, 0.5 log increments) were evaluated in the gluteus maximus muscle superfused with physiological saline solution (35°C, pH 7.4; n ≥ 5 per group). Noradrenaline (NA, non-selective αAR agonist) constricted 1A, 2A and 3A with similar potency and efficacy. Phenylephrine (PE; α1AR agonist) evoked greater (P < 0.05) constriction in 3A (inhibited by 10(-8) m prazosin; α1AR antagonist) while UK 14304 (UK; α2AR agonist) evoked greater (P < 0.05) constriction in 1A (inhibited by 10(-7) m rauwolscine; α2AR antagonist). Isoproterenol (isoprenaline; βAR agonist) dilated 1A, 2A and 3A near-maximally with similar potency and efficacy; these dilatations were inhibited by 10(-7) m propranolol (βAR antagonist) which otherwise had no effect on responses to NA, PE, or UK. Complementary experiments in the mouse cremaster muscle revealed a pattern of αAR subtype distribution that, while distinct from the gluteus maximus muscle, was consistent with that reported for the rat cremaster muscle. We conclude that functional αAR subtype distribution in arteriolar networks of skeletal muscle varies with muscle function as well as vessel branch order.
Moore
Alex W
AW
Department of Biomedical Sciences, University of Missouri, Columbia, MO 65211, USA.
Jackson
William F
WF
Segal
Steven S
SS
D058646:Adrenergic alpha-1 Receptor Agonists / Q000494:pharmacology; D058647:Adrenergic alpha-2 Receptor Agonists / Q000494:pharmacology; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000818:Animals; D001160:Arterioles / Q000378:metabolism*; D000068438:Brimonidine Tartrate; D007545:Isoproterenol / Q000494:pharmacology; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D023421:Models, Animal; D018482:Muscle, Skeletal / Q000098:blood supply*; D009638:Norepinephrine / Q000494:pharmacology; D010656:Phenylephrine / Q000494:pharmacology; D011224:Prazosin / Q000494:pharmacology; D011433:Propranolol / Q000494:pharmacology; D011810:Quinoxalines / Q000494:pharmacology; D018340:Receptors, Adrenergic, alpha-1 / Q000187:drug effects / Q000378:metabolism*; D018341:Receptors, Adrenergic, alpha-2 / Q000187:drug effects / Q000378:metabolism*
D058646:Adrenergic alpha-1 Receptor Agonists; D058647:Adrenergic alpha-2 Receptor Agonists; D000319:Adrenergic beta-Antagonists; D011810:Quinoxalines; D018340:Receptors, Adrenergic, alpha-1; D018341:Receptors, Adrenergic, alpha-2; D010656:Phenylephrine; D000068438:Brimonidine Tartrate; D011433:Propranolol; D007545:Isoproterenol; D009638:Norepinephrine; D011224:Prazosin
Circ Res. 2001 Apr 27;88(8):816-23
11325874
J Physiol. 2010 Sep 1;588(Pt 17):3321-31
20624796
Annu Rev Physiol. 1980;42:359-71
6157355
Can J Physiol Pharmacol. 1987 Aug;65(8):1649-57
2891423
Anat Embryol (Berl). 1996 Jun;193(6):515-31
8737808
J Physiol. 2001 Nov 1;536(Pt 3):977-83
11691889
Circ Res. 1991 Jul;69(1):174-84
1647277
Physiol Rev. 1981 Jan;61(1):151-247
6110212
Am J Physiol. 1993 Mar;264(3 Pt 2):H892-900
8384425
J Biol Chem. 1980 Mar 25;255(6):2301-7
6244274
J Appl Physiol (1985). 1987 Apr;62(4):1465-72
2885299
Angiologica. 1971;8(6):285-96
5157687
Am J Physiol. 1975 Mar;228(3):791-6
1115244
J Physiol. 2010 Jun 15;588(Pt 12):2269-82
20375140
Acta Physiol Scand. 1971 Apr;81(4):459-71
5091106
Circ Res. 1989 Jun;64(6):1096-105
2541942
J Physiol. 2003 Jul 15;550(Pt 2):563-74
12754308
J Physiol. 2004 Mar 1;555(Pt 2):545-63
14694145
J Physiol. 2005 Mar 15;563(Pt 3):821-9
15618269
Acta Physiol Scand. 2000 Apr;168(4):511-8
10759588
Circ Res. 1987 Nov;61(5 Pt 2):II26-31
3664985
Br J Pharmacol. 2008 Oct;155(4):514-24
18604236
Circ Res. 1990 Jun;66(6):1643-57
1971536
Circ Res. 1991 Jan;68(1):232-44
1845853
J Physiol. 1970 Mar;206(3):543-62
5498505
J Appl Physiol (1985). 1997 Nov;83(5):1575-80
9375322
Circ Res. 1988 Jan;62(1):37-50
2891454
J Appl Physiol (1985). 2004 Aug;97(2):731-8
15247201
J Appl Physiol (1985). 1997 Dec;83(6):2037-42
9390978
J Appl Physiol (1985). 2002 May;92(5):1808-16
11960928
J Physiol. 2005 Mar 1;563(Pt 2):541-55
15576454
J Pharmacol Exp Ther. 1984 Jun;229(3):823-30
6144792
J Appl Physiol (1985). 2003 Dec;95(6):2370-4
12923119
J Physiol. 2003 Nov 15;553(Pt 1):281-92
12949223
J Physiol. 2009 Feb 15;587(Pt 4):713-9
19218620
Am J Physiol. 1989 Nov;257(5 Pt 1):E736-42
2556938
Am J Physiol. 1997 Jan;272(1 Pt 2):R386-91
9039033
J Pharmacol Exp Ther. 1987 May;241(2):361-5
3033211
Br J Pharmacol. 1994 Dec;113(4):1105-12
7889261
J Appl Physiol (1985). 1997 May;82(5):1411-5
9134886
Angiologica. 1971;8(3-5):187-201
5141657
J Physiol. 1982 Nov;332:169-86
7153926
Circ Res. 1962 Sep;11:370-80
13981593
FASEB J. 2000 Jan;14(1):197-207
10627294
Am J Physiol. 1988 May;254(5 Pt 2):H919-28
3364596